<DOC>
	<DOCNO>NCT01230996</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , cisplatin , work different way stop growth tumor cell , either kill cell stop divide . Radiation therapy use high-energy x-ray kill tumor cell . Specialized radiation therapy delivers high dose radiation directly tumor may kill tumor cell cause less damage normal tissue . Giving cisplatin together radiation therapy may kill tumor cell . PURPOSE : This phase I/II trial study side effect best dose cisplatin give together radiation therapy treat patient locally advanced cervical cancer .</brief_summary>
	<brief_title>Cisplatin Radiation Therapy Treating Patients With Locally Advanced Cervical Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To determine feasibility dose-escalation chemoradiotherapy comprise cisplatin combination simultaneous-boost intensity-modulated radiotherapy ( IMRT ) patient locally advanced cervical cancer . Secondary - To assess objective response rate patient treated regimen . - To assess local control disease patient treat regimen . - To correlate toxicity dose-volume histogram data patient . OUTLINE : This multicenter , phase I , dose-escalation study follow phase II study . Patients receive cisplatin IV 1 hour weekly 5 week . Patients also undergo intensity-modulated radiotherapy 5 day week approximately 6 week . Patients complete quality-of-life questionnaire baseline , , completion study therapy . After completion study treatment , patient follow 4 12 week , every 3 month 2 year , periodically 5 year .</detailed_description>
	<mesh_term>Uterine Cervical Neoplasms</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm squamous cell carcinoma , adenocarcinoma , poorly differentiate carcinoma cervix Locally advance disease FIGO stage IIBIVA ( pelvic nodal status ) FIGO stage IB2 IIA ( pelvic nodal involvement ) Measurable disease MRI scan No evidence common iliac paraaortic nodal involvement No distant metastases PATIENT CHARACTERISTICS : WHO performance status 01 Platelet count &gt; 100 x 10^9/L White cell count &gt; 3.0 x 10^9/L Neutrophil count &gt; 1.5 x 10^9/L ALT/AST &lt; 2.5 time upper limit normal ( ULN ) Bilirubin &lt; 1.25 time ULN EDTA clearance &gt; 55 mL/min Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception No prior cancer except skin tumor No prior pelvic adhesion , inflammatory bowel disease , pelvic inflammatory disease , diabetes mellitus PRIOR CONCURRENT THERAPY : No prior pelvic radiotherapy surgery laparoscopic node dissection No concurrent anticancer investigational therapy</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>October 2010</verification_date>
	<keyword>cervical adenocarcinoma</keyword>
	<keyword>cervical adenosquamous cell carcinoma</keyword>
	<keyword>cervical squamous cell carcinoma</keyword>
	<keyword>stage IB cervical cancer</keyword>
	<keyword>stage IIA cervical cancer</keyword>
	<keyword>stage IIB cervical cancer</keyword>
	<keyword>stage III cervical cancer</keyword>
	<keyword>stage IVA cervical cancer</keyword>
</DOC>